Biopharma

As trade tensions heat up, one sector might have the immunity investors need – biopharma. JPMorgan analyst Chris Schott sees the industry as a relative “safe haven” despite looming pharmaceutical-specific tariffs, thanks to its high-margin business model and operational...

On Friday, the European Commission (EC) approved Bristol Myers Squibb & Co‘s (NYSE:BMY) Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more...

On Friday, Eton Pharmaceuticals, Inc (NASDAQ:ETON) revealed results from its bioequivalence study of ET-600, a proprietary, patented oral solution of desmopressin under development for central diabetes insipidus. Central diabetes insipidus (CDI), or arginine vasopressin deficiency, is a condition...

On Thursday, Sutro Biopharma, Inc. (NASDAQ:STRO) prioritized its antibody-drug conjugates (ADC) pipeline, including three wholly-owned preclinical programs in its next-generation ADC pipeline. Exatecan ADC targeting Tissue Factor, STRO-004, will enter the clinic in the second half of 2025. STRO-...

The global psychedelic drugs market is poised for significant growth over the next five years, with an estimated increase of USD 1.37 billion from 2024 to 2028, according to a report by Technavio. The market is projected to grow at a compound annual growth rate (CAGR) of 11.82%, fueled by the...

Eli Lilly And Co (NYSE:LLY) “could be on its way to becoming a $1 trillion market cap company,” according to analysts at Cantor Fitzgerald. The assessment comes on the heels of an earnings report that shows first-quarter revenue of $8.77 billion. That’s up 26% year-over-year,...

Eli Lilly and Company (NYSE:LLY) is set to report first-quarter earnings on Tuesday, April 30. Analysts expect the Indianapolis, Indiana-based company’s quarterly earnings to be $2.46 per share, up from $1.62 per share in the year-ago period. Eli Lilly is projected to post revenue of $8.92...

NY Mets owner billionaire Steve Cohen has bought as many as 119,092,680 ordinary shares of clinical-stage biopharmaceutical company Bionomics Limited (NASDAQ: BNOX) through his Point72 asset management firm, again showing support for the biopharma sector. See recent buy of Cybin (NYSE: CYBN)...

Shares of weight-loss drug manufacturers came to the party last week on the back of positive news flow from these companies. What Happened: Danish drug giant Novo Nordisk A/S (NYSE:NVO) said its first-half sales and net profit jumped 29% and 43% year-over-year, thanks to a 367% jump in the sales of...

Industry giant Morgan Stanley (NYSE:MS) is shaking up its model for income-focused investors, indicating a strategic move towards robust and resilient players. The multinational investment bank told investors Thursday that it added new positions and adjusted weights in its dividend portfolio. What...

Key Takeaways： As well as tapping strategic investors, Viva Biotech is planning to list its drug research subsidiary on a Chinese exchange by the end of 2026 A sinking share price has piled pressure on the company to buy back its convertible bonds, hence the need for funds By Molly Wen...

U.S. markets closed mixed on Monday as investors and traders turned their attention toward Federal Reserve Chair Jerome Powell's testimony before Congress on Tuesday and Wednesday. The Nasdaq Composite closed 0.11% lower while the S&P 500 gained 0.07%. The Dow closed 0.12% higher. Meanwhile,...

2022 would go down as one of the worst years for the financial markets. The sell-off has been all-pervasive, with stocks, bonds and cryptos all selling off indiscriminately. Even as high-fliers like Apple Inc. (NASDAQ: AAPL) and Tesla Inc. (NASDAQ: TSLA) bit the dust, there were a...

Biopharma stocks were not immune to the broader market downturn seen for much of 2022. The iShares Biotechnology ETF (NASDAQ: IBB), which is heavily weighted with large-cap biotech companies, has lost 13.2% compared to a steeper 27.8% pullback by the SPDR S&P Biotech (NYSE: XBI). What Happened...

Major Wall Street indices closed over 1% lower on Monday after protests in China against COVID-zero policies led to supply chain concerns. Oil also took a hit with the West Texas Intermediate (WTI) futures briefly hitting their 11-month low during Asian trading over demand worries. Investors and...